In vitro biochemical assays make possible the high throughput screening (HTS) of large compound libraries. A successful HTS campaign is typically viewed as one that identifies large numbers of diverse chemical series hits as potential starting points on the way to a clinical candidate. These hits are typically weakly active in a primary screen and do not necessarily possess drug like characteristics. Hit-to-Lead optimization is now a key process in drug discovery that explores the chemistry and biology of hits to focus efforts on the most promising starting points so that development time and costs are saved. What makes a promising starting point for a drug discovery program? In this webinar, strategies to triage hits and focus efforts will be discussed. This webinar is presented by Mark Wolf, Head, Medicinal Chemistry, AMRI and Doug Kitchen, Head, CADD, AMRI.Watch webinar replay
More from Curia
The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate fro...